Carsten Dehning has well over 15 years of experience in the biotech industry where he has been involved in the management of early stage discovery ventures to projects from early to late stages of clinical development. His professional career includes serving as CFO and member of the Management Board of DeveloGen AG, Germany where he was instrumental in all of the company’s corporate and business development transactions including its sale to Evotec AG in 2010. As CEO of Aspireo Pharmaceutical Ltd, Carsten was leading the clinical and corporate development of the company’s sole asset leading to a successful exit in 2015. As Acting CFO of Albireo Ltd, he was part of the team that took the company through successful licensing of its lead compound as well as the subsequent repositioning of the company culminating in a reverse merger on NASDAQ in 2016. Carsten joined Biovertis/Morphochem in 2017 and as its CEO and CFO he is leading the design and execution of the company’s corporate development efforts. He holds a Diploma in business administration from the University of Göttingen, Germany.